Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women

Johannes D Veldhuis, James M. Patrie, Kirsten Frick, Judith Y. Weltman, Arthur L. Weltman

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: A recent study indicated that twice-daily s.c. administration of a high dose of recombinant human GHRH-1,44-amide (GHRH) for 90 days can alter body composition in healthy older men. No data establish whether this is also true in postmenopausal women. The present study tests the hypothesis that the same GHRH regimen applied in women will: (i) elevate both IGF-I and GH concentrations; and (ii) reduce abdominal visceral fat mass, augment total body water and enhance functional performance. Design: Ten postmenopausal volunteers underwent baseline study and then received 1 mg GHRH twice daily s.c. for 3 months. Methods: Statistical comparisons were made with preintervention baseline data. Results: GHRH administration stimulated: (i) a mean 98±14% elevation of overnight GH concentrations after administration of the peptide for 1 and 3 months (P < 0.005); (ii) a sustained 71±3.5% rise in IGF-I concentrations over the interval from 2 weeks to 3 months (P < 0.0012); (iii) a 16±7% reduction in abdominal visceral fat mass (P = 0.029) and a 14±5% increase in tritiated water space (P < 0.025); (iv) an abbreviation of the times required to walk 30 m (P = 0.015) and ascend two flights of stairs (P = 0.003). Most (70%) subjects experienced local skin reactivity. There were no systemic adverse events. Conclusions: A 3-month regimen of GHRH supplementation in postmenopausal women can stimulate GH and IGF-I production, reduce abdominal visceral fat and improve selected measures of physical performance, while inducing significant local skin reactivity.

Original languageEnglish (US)
Pages (from-to)669-677
Number of pages9
JournalEuropean Journal of Endocrinology
Volume153
Issue number5
DOIs
StatePublished - Nov 2005

Fingerprint

Growth Hormone-Releasing Hormone
Intra-Abdominal Fat
Insulin-Like Growth Factor I
Amides
Skin
Body Water
Body Composition
Volunteers
Peptides
Water

ASJC Scopus subject areas

  • Endocrinology

Cite this

Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women. / Veldhuis, Johannes D; Patrie, James M.; Frick, Kirsten; Weltman, Judith Y.; Weltman, Arthur L.

In: European Journal of Endocrinology, Vol. 153, No. 5, 11.2005, p. 669-677.

Research output: Contribution to journalArticle

Veldhuis, Johannes D ; Patrie, James M. ; Frick, Kirsten ; Weltman, Judith Y. ; Weltman, Arthur L. / Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women. In: European Journal of Endocrinology. 2005 ; Vol. 153, No. 5. pp. 669-677.
@article{61c45195b4ba4217af9e662394268347,
title = "Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women",
abstract = "Objective: A recent study indicated that twice-daily s.c. administration of a high dose of recombinant human GHRH-1,44-amide (GHRH) for 90 days can alter body composition in healthy older men. No data establish whether this is also true in postmenopausal women. The present study tests the hypothesis that the same GHRH regimen applied in women will: (i) elevate both IGF-I and GH concentrations; and (ii) reduce abdominal visceral fat mass, augment total body water and enhance functional performance. Design: Ten postmenopausal volunteers underwent baseline study and then received 1 mg GHRH twice daily s.c. for 3 months. Methods: Statistical comparisons were made with preintervention baseline data. Results: GHRH administration stimulated: (i) a mean 98±14{\%} elevation of overnight GH concentrations after administration of the peptide for 1 and 3 months (P < 0.005); (ii) a sustained 71±3.5{\%} rise in IGF-I concentrations over the interval from 2 weeks to 3 months (P < 0.0012); (iii) a 16±7{\%} reduction in abdominal visceral fat mass (P = 0.029) and a 14±5{\%} increase in tritiated water space (P < 0.025); (iv) an abbreviation of the times required to walk 30 m (P = 0.015) and ascend two flights of stairs (P = 0.003). Most (70{\%}) subjects experienced local skin reactivity. There were no systemic adverse events. Conclusions: A 3-month regimen of GHRH supplementation in postmenopausal women can stimulate GH and IGF-I production, reduce abdominal visceral fat and improve selected measures of physical performance, while inducing significant local skin reactivity.",
author = "Veldhuis, {Johannes D} and Patrie, {James M.} and Kirsten Frick and Weltman, {Judith Y.} and Weltman, {Arthur L.}",
year = "2005",
month = "11",
doi = "10.1530/eje.1.02019",
language = "English (US)",
volume = "153",
pages = "669--677",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "5",

}

TY - JOUR

T1 - Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women

AU - Veldhuis, Johannes D

AU - Patrie, James M.

AU - Frick, Kirsten

AU - Weltman, Judith Y.

AU - Weltman, Arthur L.

PY - 2005/11

Y1 - 2005/11

N2 - Objective: A recent study indicated that twice-daily s.c. administration of a high dose of recombinant human GHRH-1,44-amide (GHRH) for 90 days can alter body composition in healthy older men. No data establish whether this is also true in postmenopausal women. The present study tests the hypothesis that the same GHRH regimen applied in women will: (i) elevate both IGF-I and GH concentrations; and (ii) reduce abdominal visceral fat mass, augment total body water and enhance functional performance. Design: Ten postmenopausal volunteers underwent baseline study and then received 1 mg GHRH twice daily s.c. for 3 months. Methods: Statistical comparisons were made with preintervention baseline data. Results: GHRH administration stimulated: (i) a mean 98±14% elevation of overnight GH concentrations after administration of the peptide for 1 and 3 months (P < 0.005); (ii) a sustained 71±3.5% rise in IGF-I concentrations over the interval from 2 weeks to 3 months (P < 0.0012); (iii) a 16±7% reduction in abdominal visceral fat mass (P = 0.029) and a 14±5% increase in tritiated water space (P < 0.025); (iv) an abbreviation of the times required to walk 30 m (P = 0.015) and ascend two flights of stairs (P = 0.003). Most (70%) subjects experienced local skin reactivity. There were no systemic adverse events. Conclusions: A 3-month regimen of GHRH supplementation in postmenopausal women can stimulate GH and IGF-I production, reduce abdominal visceral fat and improve selected measures of physical performance, while inducing significant local skin reactivity.

AB - Objective: A recent study indicated that twice-daily s.c. administration of a high dose of recombinant human GHRH-1,44-amide (GHRH) for 90 days can alter body composition in healthy older men. No data establish whether this is also true in postmenopausal women. The present study tests the hypothesis that the same GHRH regimen applied in women will: (i) elevate both IGF-I and GH concentrations; and (ii) reduce abdominal visceral fat mass, augment total body water and enhance functional performance. Design: Ten postmenopausal volunteers underwent baseline study and then received 1 mg GHRH twice daily s.c. for 3 months. Methods: Statistical comparisons were made with preintervention baseline data. Results: GHRH administration stimulated: (i) a mean 98±14% elevation of overnight GH concentrations after administration of the peptide for 1 and 3 months (P < 0.005); (ii) a sustained 71±3.5% rise in IGF-I concentrations over the interval from 2 weeks to 3 months (P < 0.0012); (iii) a 16±7% reduction in abdominal visceral fat mass (P = 0.029) and a 14±5% increase in tritiated water space (P < 0.025); (iv) an abbreviation of the times required to walk 30 m (P = 0.015) and ascend two flights of stairs (P = 0.003). Most (70%) subjects experienced local skin reactivity. There were no systemic adverse events. Conclusions: A 3-month regimen of GHRH supplementation in postmenopausal women can stimulate GH and IGF-I production, reduce abdominal visceral fat and improve selected measures of physical performance, while inducing significant local skin reactivity.

UR - http://www.scopus.com/inward/record.url?scp=27944501502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944501502&partnerID=8YFLogxK

U2 - 10.1530/eje.1.02019

DO - 10.1530/eje.1.02019

M3 - Article

C2 - 16260425

AN - SCOPUS:27944501502

VL - 153

SP - 669

EP - 677

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 5

ER -